Having Both Hypertension and Type 2 Diabetes Nearly Triples Cardiovascular Death Risk
A 20-year U.S. study finds concurrent hypertension and T2D doubles all-cause mortality risk and nearly triples cardiovascular death risk.
Summary
A prospective study of nearly 49,000 U.S. adults from NHANES 1999–2018 found that having both hypertension and type 2 diabetes simultaneously was associated with 2.46 times higher all-cause mortality and 2.97 times higher cardiovascular mortality compared to having neither condition. The burden of concurrent disease doubled from 6% to 12% over the study period. Associations were stronger in females than males, and varied by race and ethnicity. Even concurrent prediabetes and elevated blood pressure predicted up to 19% higher mortality risk. These findings highlight a critical and growing public health burden demanding targeted, context-sensitive interventions.
Detailed Summary
Hypertension and type 2 diabetes (T2D) are two of the most prevalent chronic conditions in the United States, and they frequently co-occur. Yet the combined mortality burden of having both conditions simultaneously has been understudied, particularly with respect to differences by sex, race, and ethnicity. This analysis addresses that gap using two decades of nationally representative data.
Researchers analyzed 48,727 adults from the National Health and Nutrition Examination Surveys (NHANES) conducted between 1999 and 2018, linked to national death records. Participants were classified into four mutually exclusive groups: no hypertension and no T2D, hypertension only, T2D only, or concurrent hypertension and T2D. Primary outcomes were all-cause mortality and cardiovascular mortality, defined using ICD-10 codes. Kaplan-Meier survival curves and multivariable Cox proportional hazards models were used, adjusting for demographic and clinical confounders.
Over a median follow-up of 9.2 years, 7,734 deaths occurred. The prevalence of concurrent hypertension and T2D doubled from 6% to 12% between 1999 and 2018. Individuals with both conditions faced a 2.46-fold higher risk of all-cause mortality (95% CI: 2.45–2.47) and a 2.97-fold higher risk of cardiovascular mortality (95% CI: 2.94–3.00) compared to those with neither condition. Compared to having only one condition, concurrent disease was associated with up to 66% higher all-cause mortality and more than twofold higher cardiovascular mortality risk.
Notably, sex-based differences were significant: females with both conditions faced stronger associations with mortality than males (P for interaction <0.01). Differences by race and ethnicity were also observed, highlighting the importance of disaggregated analyses in understanding disparate health outcomes. Even sub-clinical combinations—concurrent prediabetes and elevated blood pressure—were associated with up to 19% higher mortality risk versus having neither, suggesting a continuum of compounding risk.
These findings carry urgent clinical and public health implications. The doubling of concurrent hypertension and T2D prevalence over two decades, combined with the dramatically elevated mortality risk these conditions together confer, underscores the need for integrated, multimorbidity-focused care models. The sex and race/ethnicity disparities further argue for individualized, equity-centered interventions aimed at extending healthspan across diverse U.S. populations.
Key Findings
- Concurrent hypertension and T2D predicted 2.46x higher all-cause and 2.97x higher cardiovascular mortality vs. neither condition.
- Prevalence of both conditions simultaneously doubled from 6% to 12% between 1999 and 2018.
- Mortality associations were significantly stronger in females than males (P for interaction <0.01).
- Having both conditions raised all-cause mortality up to 66% and cardiovascular mortality over 2x vs. having only one.
- Even concurrent prediabetes and elevated blood pressure linked to up to 19% higher mortality risk.
Methodology
Prospective cohort study using NHANES 1999–2018 data linked to national mortality records (n=48,727). Participants were followed for a median of 9.2 years with outcomes defined by ICD-10 codes. Multivariable Cox proportional hazards models and Kaplan-Meier curves were used, with interaction terms tested for sex and race/ethnicity.
Study Limitations
Disease status was ascertained at baseline only, potentially misclassifying participants who developed conditions later during follow-up. Self-reported diagnoses and reliance on survey data may introduce measurement error. Residual confounding from unmeasured lifestyle or socioeconomic factors cannot be excluded.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.